Elan Corp Plc has signed an agreement with Britain’s Cambridge University to create a research center focused on therapies for Alzheimer’s and Parkinson’s, the Dublin-headquartered biotech group said on Sunday.
Popular Posts:
- Irish drugmaker Elan suffers $43.6M net loss in Q3
- Analytical Breakthroughs Ease Health Care Reform
- Medical journals retract “unethical” research
- Blacks win fewer health research grants in U.S.
- Blacks win fewer health research grants in U.S.